Sugi Predict

Sugi Predict / Compounds / SCHEMBL692983

SCHEMBL692983

SCHEMBL692983

CC(C)(C)OC(=O)N1CCCCC1C1(O)CNC1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ HSD11B1 P28845 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ KDM1A O60341 1/20 0.38
▸ PDE8B O95263 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1488763 1.00 HSD17B10 (0.41) HSD17B10HPGDHSD11B1NPC1EPHX1
SCHEMBL25970274 0.85 HSD17B10 (0.46) HSD17B10HPGDHSD11B1NPC1EPHX1
SCHEMBL25983994 0.84 HSD17B10 (0.45) HSD17B10HPGDHSD11B1NPC1EPHX1
SCHEMBL28521198 0.82 HSD17B10 (0.48) HSD17B10HPGDHSD11B1NPC1ALDH1A1
SCHEMBL22725305 0.82 HSD17B10 (0.48) HSD17B10HPGDHSD11B1NPC1ALDH1A1
SCHEMBL22725293 0.82 HSD17B10 (0.48) HSD17B10HPGDHSD11B1NPC1ALDH1A1
SCHEMBL28952628 0.82 HSD17B10 (0.46) HSD17B10HPGDHSD11B1NPC1EPHX1
SCHEMBL25970105 0.81 HSD17B10 (0.50) HSD17B10HPGDHSD11B1NPC1ALDH1A1
SCHEMBL25970081 0.81 HSD17B10 (0.50) HSD17B10HPGDHSD11B1NPC1ALDH1A1
SCHEMBL25970131 0.79 HSD17B10 (0.49) HSD17B10HPGDHSD11B1NPC1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250100966-A1 MEK INHIBITORS AND METHODS OF THEIR USE EXELIXIS INC (US) 2025-03-27 — — US disclosed
US-11597699-B2 MEK inhibitors and methods of their use EXELIXIS, INC. (US) 2023-03-07 — — US disclosed
CN-109053523-B Azetidines as MEK inhibitors for the treatment of proliferative diseases 埃克塞利希斯股份有限公司 2022-03-25 — — CN disclosed
CN-111643496-A Methods of using MEK inhibitors 埃克塞利希斯股份有限公司 2020-09-11 — — CN disclosed
US-20200283383-A1 MEK Inhibitors and Methods of Their Use EXELIXIS, INC. 2020-09-10 — — US disclosed
US-20200031770-A1 MEK INHIBITORS AND METHODS OF THEIR USE EXELIXIS, INC. 2020-01-30 — — US disclosed
CN-110668988-A Azetidines as MEK inhibitors for the treatment of proliferative diseases 埃克塞利希斯股份有限公司 2020-01-10 — — CN disclosed
US-20190144382-A1 MEK Inhibitors and Methods of Their Use EXELIXIS, INC. 2019-05-16 — — US disclosed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
US-20170166523-A9 MEK Inhibitors And Methods Of Their Use EXELIXIS, INC. 2017-06-15 — — US disclosed
US-7803839-B2 anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol EXELIXIS, INC. (US) 2010-09-28 — — US disclosed
CN-101605540-A Methods of using MEK inhibitors EXELIXIS INC (US) 2009-12-16 — — CN disclosed
US-20090275606-A1 Heterocyclic Compounds as MEK Inhibitors NOVARTIS AG 2009-11-05 — — US disclosed
EP-2101759-A1 METHODS OF USING MEK INHIBITORS Exelixis, Inc. (US) 2009-09-23 — — EP disclosed
US-20090156576-A1 anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol EXELIXIS INC. (US) 2009-06-18 — — US disclosed
WO-2008124085-A2 METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS EXELIXIS, INC. (US) 2008-10-16 — — WO disclosed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US disclosed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 — — WO disclosed
EP-1934174-A1 AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2008-06-25 — — EP disclosed
WO-2007044515-A1 AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166523-A9 MEK Inhibitors And Methods Of Their Use BRAF, NRAS, MAP3K1 HSD17B10 2075/4885HPGD 391/4885HSD11B1 1220/4885
US-20200283383-A1 MEK Inhibitors and Methods of Their Use BRAF, NRAS, MAP3K20 HSD17B10 1885/4885HPGD 413/4885HSD11B1 1159/4885
US-20090156576-A1 anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol NRAS, BRAF, KRAS HSD17B10 2400/4885HPGD 492/4885HSD11B1 2133/4885
US-20250100966-A1 MEK INHIBITORS AND METHODS OF THEIR USE BRAF, NRAS, KRAS HSD17B10 2315/4885HPGD 387/4885HSD11B1 1307/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS HSD17B10 1813/4885HPGD 718/4885HSD11B1 832/4885
US-20090275606-A1 Heterocyclic Compounds as MEK Inhibitors NRAS, BRAF, MAP3K1 HSD17B10 1812/4885HPGD 256/4885HSD11B1 938/4885
US-20190144382-A1 MEK Inhibitors and Methods of Their Use BRAF, NRAS, MAP3K20 HSD17B10 1885/4885HPGD 413/4885HSD11B1 1159/4885
US-11597699-B2 MEK inhibitors and methods of their use BRAF, NRAS, MAP3K20 HSD17B10 1885/4885HPGD 413/4885HSD11B1 1159/4885
US-20200031770-A1 MEK INHIBITORS AND METHODS OF THEIR USE BRAF, NRAS, MAP3K20 HSD17B10 1885/4885HPGD 413/4885HSD11B1 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.